HTG Molecular Diagnostics, Inc. (HTGMQ)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Jul 1, 2025
Market Cap221.00
Revenue (ttm)6.21M
Net Income (ttm)-20.15M
Shares Out2.21M
EPS (ttm)-15.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume400
Average Volume4,514
Open0.0001
Previous Close0.0001
Day's Range0.0001 - 0.0001
52-Week Range0.0000 - 0.0150
Beta-50.93
RSI44.93
Earnings Daten/a

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company dist... [Read more]

Sector Healthcare
Founded 1997
Employees 54
Stock Exchange OTCMKTS
Ticker Symbol HTGMQ
Full Company Profile

Financial Performance

In 2022, HTG Molecular Diagnostics's revenue was $6.37 million, a decrease of -28.52% compared to the previous year's $8.91 million. Losses were -$21.59 million, 26.0% more than in 2021.

Financial Statements

News

There is no news available yet.